PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis. (26th November 2022)

• Record Type: Journal Article
• Authors: Ying, Zhang; Qi, Du; Chaoran, Wang; Min, Hu; Miao, Wang; Qin, Li
• Is Part Of: Cancer investigation. Volume 40:Number 10(2022)
• Page Start: 889
• Page End: 900
• Publication Date: 2022-11-26
• Subjects: PARP inhibitor -- ovarian cancer -- maintenance therapy -- first-line -- meta-analysis; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2022.2088780
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Background: To illustrate the accurate location of Poly-ADP-ribose polymerase inhibitor (PARPi) as the first-line maintenance therapy in advanced ovarian cancer (AOC). Methods: Search for eligible studies and calculate clinical outcomes. Results: PARPi as a first-line maintenance treatment significantly prolonged the BRCAmut population and the homologous recombination deficiency (HRD) positive population. Conclusion: PARPi as first-line maintenance therapy significantly improves the progression-free survival in AOC, especially in the BRCAmut and HRD positive populations. PARPi has been becoming the standard first-line maintenance therapy for AOC.